An insight into NIH’s Big Data to Knowledge project

DNAdigest– official supporter of BioData World Congress USA, interviewed Phil Bourne – Associate Director for Data Science at the National Institutes of Health about the Big Data to Knowledge (BD2K) project. What is Big Data to Knowledge (BD2K)? “BD2K is an NIH program across 27 institutes of about 110 million dollars a year. The program focus is on the challenges emerging in data across biosciences, …

Stem Cells Live: Generation of Clinical-Grade iPSCs

Today’s afternoon session on iPS Cell Industrialisation kicked off with a talk by Dr Thomas Fellner, Head of Business Development, Cell Therapy Development Services at Lonza, about the generation of clinical-grade iPSCs. Since the discovery of iPSCs by Yamanaka and co-workers, there has been much excitement about their potential, and several groups have been working on translating iPSCs to the …

Evaluating the Discovering New Therapeutic Uses for Existing Molecules program

In putting the agenda and speakers together for the World Drug Repositioning Congress USA, I came up with a lot of opposing views on the NIH's pilot program on the subject. Of course that for a pilot program, there are no expectations that the project will be flawless, in the meantime it should be targeted to really encourage and set …

“Crowd sourcing drug development”. Can it really lead to drug repositioning?

After the NCATS pilot program ‘Discovering New Therapeutic Uses for Existing Molecules' was launched in May, a lot has been discussed about its potential and the actual feasibility to reposition one or some of the 58 compounds contributed by the eight big pharma joining the project. Experts in the field of drug repurposing say that there's very little opportunity for …